Clinical Study

Postoperative Analgesic Effects of Different Doses of Epidural Hydromorphone Coadministered with Ropivacaine after Cesarean Section: A Randomized Controlled Trial

Meijuan Yang, Luyang Wang, Hong Chen, Yuwen Tang, and Xinzhong Chen

Department of Anesthesiology, Women’s Hospital, School of Medicine, Zhejiang University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China

Correspondence should be addressed to Xinzhong Chen; chenxinz@zju.edu.cn

Received 24 June 2018; Accepted 22 January 2019; Published 3 March 2019

Academic Editor: Parisa Gazerani

Copyright © 2019 Meijuan Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Single dose of epidural hydromorphone has been introduced to serve as an alternative method for postcesarean section analgesia. However, optimal dose of epidural hydromorphone remains unknown. Hence, we evaluated and compared the analgesic and adverse effects of postoperative different doses of epidural hydromorphone coadministered with ropivacaine after cesarean section.

Methods. Eighty term parturients with elective cesarean section under epidural anesthesia were allocated into four groups. Epidural analgesia was administered with an epidural bolus of either 0 mg (group H0), or 0.2 mg (group H1), or 0.4 mg (group H2), or 0.6 mg (group H3) hydromorphone coadministered with ropivacaine. The primary outcome was the visual analogue pain scores (VAPSs) and rescue opioid consumption (PCIA with sufentanil) in 24 hours. Adverse effects such as respiratory depression, pruritus, nausea, and vomiting were recorded.

Results. The VAPSs of group H1 at 2, 4, 6, 12 h and 24 h after surgery was similar to group H0. The VAPSs of group H2 at 4 and 6 h postoperatively were significantly decreased when compared to group H0. But, the VAPSs of group H3 at 2, 12, and 24 h postoperatively were similar to those of group H0. The VAPSs of group H3 at 4, 6, 12 h, and 24 h after surgery were significantly decreased when compared to those of group H0. The total sufentanil consumption in 24 hours was 90 ± 26 μg in group H0, 75 ± 29 μg in group H1, 54 ± 32 μg in group H2, and 15 ± 16 μg in group H0. Adverse effects were comparable in the four groups. Conclusions. Epidural administration of 0.6 mg hydromorphone coadministered with ropivacaine after cesarean section provided satisfactory pain relief with less sufentanil consumption. This trial is registered with ChiCTR-IPR-16010026.

1. Introduction

It is well known that the pain after cesarean section is usually ranked moderate to severe [1]. Adequate pain control after cesarean section with minimal adverse effects is important because women require a rapid recovery to ambulate and take care of their babies. Epidural analgesia generally provides superior postoperative pain relief compared to intravenous analgesia [2, 3]. Traditionally, epidural administration of opioids has been successfully used in bolus, continuous infusion, and patient-controlled epidural analgesia (PCEA) for pain control after cesarean section. A single dose of epidural morphine provides higher-quality analgesia compared with parenteral opioids [4], and it is commonly used due to its ease of application and low cost. But, the major drawbacks of morphine are its undesirable side effects, such as pruritus, nausea, and vomiting.

The hydrophilic properties of morphine make it ideal for long-acting analgesic. Owing to the high degree of hydrophilicity (octanol buffer distribution coefficient of 1), epidural morphine could provide highly effective analgesic with slow onset and longer duration but it is often accompanied by prolonged opioid side effects [5]. Hydromorphone, which was introduced into clinical practice in the 1920s, is not as extreme as morphine: it has moderate hydrophilicity (octanol buffer distribution coefficient of 525) [6]. Due to its hydrophilicity, epidural hydromorphone could cross the blood-brain barrier faster and provide fast onset and modest...
duration of action clinically [7, 8]. Neuraxial hydromorphone had been shown to be as effective as morphine for postoperative analgesia in nonobstetric or obstetric patients with potentially lower incidence of adverse effect profile [9–11], so hydromorphone is a reasonable alternative to morphine for postcesarean section analgesia. Though there have been many postoperative analgesia studies with epidural hydromorphone, what remains to be determined is the appropriate dose. While several studies have determined the optimal dose for epidural morphine postoperatively [12], few similar studies exist for hydromorphone. In the present prospective and randomized study, we evaluated and compared the analgesic and adverse effects of postoperative epidural administration of different doses of hydromorphone coadministered with a fixed dose of ropivacaine after cesarean section.

2. Materials and Methods

The study protocol was approved by ethics committees of Women’s Hospital, School of Medicine, Zhejiang University, 80 American Society of Anesthesiologists (ASA) I-II patients aged between 21 and 45 years scheduled for elective lower segment cesarean section were enrolled after signing their informed written consent. Exclusion criteria were patient’s refusal, contraindication to epidural anesthesia (e.g., infection at the intended site of epidural needle insertion and neurologic defects such as transverse myelitis), severe pregnancy-induced hypertension, history of long-term opioid consumption, and history of allergy to any of the study medications.

Routine monitoring with 3-lead electrocardiogram (ECG), peripheral oxygen saturation (SpO₂), and non-invasive blood pressure (NBP) was performed throughout the operation. Before anaesthesia, parturients were hydrated with lactated Ringer’s solution 10 ml/kg for prehydration. Epidural anaesthesia was performed with the patient in the lateral decubitus position at the L1-2 or L2-3 interspace using the loss of resistance to saline technique with an epidural needle. After test dose of 3 ml 3% chloroprocaine, 3-4 cm of the closed end, a multiorifice epidural catheter was inserted into the epidural space and secured. A T4 sensory level to pinprick was achieved using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic analgesia pump occupied with sufentanil using an electronic ana...
shown). None of the patients required additional analgesic during the intraoperative period.

The results for postoperative pain and sufentanil used were shown in Table 2. The VAPSs of group H1 and the additional sufentanil requirement in 0–24 h period after surgery were similar to group H0 (control group). The VAPSs of group H2 at 4 h and 6 h postoperatively and the total sufentanil consumption were significantly decreased when compared to group H0 \( (P < 0.05) \). The VAPSs of group H3 at 4, 6, 12 h, and 24 h after surgery and total sufentanil used were significantly decreased when compared to group H0 \( (P < 0.05) \).

Table 3 shows the results of side effects. There was no significant difference in the incidence of nausea, vomiting, pruritus, and in the received antiemetics at the 24 h postoperatively between the groups. All the pruritus were mild in nature, and no patient required any treatment. There were no reported episodes of significant respiratory depression. No patient received naloxone.

5. Discussion

Single-dose epidural opioid can offer high-quality analgesia postoperatively, and it is commonly used without the need for an expensive pump. Epidural morphine is widely used to achieve postoperative pain control, but it still causes prolonged opioid side effects [14]. Some researchers try to find a substitute of morphine for postcesarean analgesia. Hydromorphone was selected as one of these analgesics; we assumed that adding hydromorphone to the epidural anaesthetic might provide satisfactory pain control during the first 24 h postoperative hours. In our present study during the first 2 h postoperatively, the VAPSs were low and similar in the four groups. In the 4 h and 6 h after surgery, both groups H2 and H3 showed lower VAPSs than group H0. In the 12 h and 24 h after surgery, only group H3 showed lower VAPSs than group H0. The patient in group H3 applied the lowest dose of sufentanil in the four groups. Above these, we can conclude that 0.6 mg epidural hydromorphone provided satisfactory pain relief with reduced analgesic requirement in the first 24 h after surgery.

Epidural hydromorphone provides good pain relief and has side effects similar to morphine. To limit major and minor opioid side effects, the use of low-dose epidural opioids has been advocated. In a recent study, Marroquin et al. found that epidural injection of 0.6 mg hydromorphone provided good postoperative analgesia and only 25% of patients requested antipuritic medication [15]. In Chestnut’s research, using epidural hydromorphone 1 mg, the rate of pruritus was up to 58% [16]. Therefore, we thought that epidural hydromorphone in a dose of 0.6 mg would be enough for managing acute postoperative pain after cesarean section but with unpredictable pruritus. Singh et al. showed that 1.5 mg epidural morphine provided noninferior postcesarean analgesia with fewer adverse effects compared with 3 mg epidural morphine [17]. In our hospital, we commonly use 1.5–2 mg of epidural morphine for the postcesarean analgesia. Because there are inadequate data concerning the equianalgesic ratio of epidural morphine to epidural hydromorphone, we chose the ratio 5:1–10:1 for parenteral morphine to parenteral hydromorphone [18, 19]. And considering that the side-effect profile appears better with lower doses of epidural hydromorphone, we chose to use 0.2 mg, 0.4 mg, and 0.6 mg epidural hydromorphone to seek the optimal dose of epidural hydromorphone for the pain control postoperatively.

Nausea and vomiting are commonly seen with epidural opioid administration. Shulman et al. found the incidence of

### Table 1: Demographic and obstetric data.

|                  | Group H0 (n = 20) | Group H1 (n = 20) | Group H2 (n = 20) | Group H3 (n = 20) |
|------------------|------------------|------------------|------------------|------------------|
| Age (years)      | 32 ± 4           | 32 ± 4           | 33 ± 3           | 33 ± 3           |
| Weight (kg)      | 71 ± 6           | 69 ± 6           | 69 ± 8           | 70 ± 7           |
| Height (cm)      | 162 ± 4          | 161 ± 3          | 160 ± 4          | 160 ± 4          |
| BMI (kg/m²)      | 27 ± 2           | 27 ± 2           | 27 ± 2           | 27 ± 3           |
| Gestation (weeks)| 38 ± 1           | 38 ± 2           | 38 ± 1           | 38 ± 1           |
| Operation time (min) | 47 ± 9     | 45 ± 10          | 44 ± 13          | 41 ± 9           |

Data are mean ± SD. BMI = body mass index.

### Table 2: Results for VAPSs at 2, 4, 6, 12, and 24 h after injecting epidural hydromorphone and total analgesic requirement (PCA with sufentanil) in the first 24 h.

|                  | Group H0 (n = 20) | Group H1 (n = 20) | Group H2 (n = 20) | Group H3 (n = 20) |
|------------------|------------------|------------------|------------------|------------------|
| 2 h              | 0.9 ± 0.6        | 0.95 ± 0.5       | 0.65 ± 0.6       | 0.6 ± 0.5        |
| 4 h              | 2.8 ± 0.9        | 2.4 ± 0.7        | 1.3 ± 0.9        | 0.7 ± 0.6        |
| 6 h              | 2.8 ± 0.7        | 2.7 ± 0.7        | 2.1 ± 0.7        | 0.8 ± 0.7        |
| 12 h             | 3.1 ± 0.8        | 2.9 ± 0.7        | 2.8 ± 0.6        | 1.0 ± 0.9        |
| 24 h             | 3.2 ± 0.7        | 3.1 ± 0.6        | 3.2 ± 0.7        | 2.5 ± 0.8        |
| Total sufentanil required at 24 h (μg) | 90 ± 26 | 75 ± 29 | 54 ± 32 | 15 ± 16 |

Data are mean ± SD. *P < 0.05 versus group H0. VAPSs = visual analogue pain scores. PCA = patient-controlled intravenous analgesia.

### Table 3: Side effects in the 24 hours after surgery.

|                  | Group H0 (n = 20) | Group H1 (n = 20) | Group H2 (n = 20) | Group H3 (n = 20) |
|------------------|------------------|------------------|------------------|------------------|
| Nausea           | 5                | 5                | 4                | 4                |
| Vomiting         | 2                | 1                | 1                | 1                |
| Antiemetic used  | 0                | 0                | 0                | 1                |
| Pruritus         | 0                | 0                | 1                | 4                |
| Respiratory      | 0                | 0                | 0                | 0                |

Data are presented as the number of patients.
nausea and vomiting was 9% with epidural hydromorphone [20]. Palmer et al. in a dose-response study examined different doses of epidural morphine (0, 1.25, 2.5, 3.75, or 5 mg), the quality of analgesia, and side effects in 60 parturients [21]. Quality of analgesia increased as the dose of epidural morphine was increased up to 3.75 mg; however, increasing the dose further to 5.0 mg did not enhance analgesia, and pruritus increased with the dose of epidural morphine. But, in our study, we did not find the epidural hydromorphone increased nausea in a dose-dependent manner; we found no statistically significant difference between the four groups. There were many factors influencing the occurrence of nausea and vomiting. Firstly, when the parturients did not gain good pain relief, they would use the PCIA. It was not surprising that we found no differences in the side-effect profiles as sufentanyl had similar adverse events. Secondly, in patients who undergo cesarean delivery with epidural anesthesia, these problems can be aggravated by uterine manipulation and peritoneal closure. For these reasons, it was necessary to use an antiemetic preventively. In our study, we used intravenous tropisetron 5 mg intraoperatively for nausea and vomiting prophylaxis.

Pruritus is a common and troublesome side effect of epidural opioid administration after cesarean section. Shulman et al. reported pruritus in one of the 21 patients who received single bolus of epidural hydromorphone (1.25–1.5 mg) [20]. Marroquin et al. found that pruritus occurred in 25% patients while adding 0.6 mg hydromorphone to epidural space [15]. In our present study, the occurrence of pruritus was low in all groups. Though the rate of pruritus is high in group H3, there is no statistically significant difference between groups. More researches should be carried out to find out what role hydromorphone plays in pruritus. Respiratory depression is the most worrisome complication and may occur within minutes or be delayed for hours after injection. Although respiratory depression has been reported after 1 mg of epidural hydromorphone [22], we found no patient with this feared side effect; all patients should be closely monitored in the first 24 h after surgery.

Several limitations existed in our present study. First, we did not clearly record the onset time and duration of pain relief with epidural hydromorphone. Second, the use of sufentanyl consumption as our primary outcome to measure analgesic efficacy may be modulated by the mother if she is worried that opioids may affect her or her baby. Third, we investigated just three doses of epidural hydromorphone for postoperative analgesia, if we had studied four or more larger different doses, the result may be different and more information related to side-effect profile of epidural hydromorphone would be known. Our next step is to study the median effective dose (ED50) of epidural hydromorphone for postoperative pain relief at 24 h and to identify what side effects are present at that dose.

6. Conclusion

Hydromorphone has been proposed as an alternative for morphine due to its similar lipophilicity (hydromorphone 1.11–1.35 vs. morphine 0.70–1.39) and analgesic efficacy [23]. Our study showed that 0.6 mg epidural hydromorphone could be an appropriate dose for the treatment of acute postoperative pain after cesarean section. This is a one-step study in determining a safe and effective dosage of epidural hydromorphone for postsurgical analgesia. Additional research is needed to compare both efficacy and side effects between hydromorphone and morphine.

Abbreviations

PCIA: Patient-controlled intravenous analgesia
VAS: Visual analogue scale
ECG: Electrocardiogram
SpO2: Peripheral oxygen saturation
NBP: Noninvasive blood pressure
BMI: Body mass index
ED50: Median effective dose.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

This study was approved by the Ethics Committee of Women’s Hospital, School of Medicine, Zhejiang University (No. 20170020).

Consent

Written informed consent was obtained from all participants.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors contributed substantially to this manuscript. MY, XC, HC, YT, and LW were involved in the design of the study. MY, YT, and LW were involved in collecting the data. MY, HC, and XC helped in analyzing the data. MY, YT, and HC were responsible for interpretation of data. MY and XC helped in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank all staff in the Department of Anesthesia and operating room of Women’s Hospital, School of Medicine, Zhejiang University. The authors would also like to express their gratitude to all patients participated in this study. This work was supported by the fund from National Natural Science Foundation of China (NSFC; nos. 81471126 and 81271237).
References

[1] S. Kerai, K. N. Saxena, and B. Taneja, "Post-caesarean analgesia: what is new?", *Indian Journal of Anaesthesia*, vol. 61, no. 3, pp. 200–214, 2017.

[2] A. M. Stroud, D. D. Tulanont, T. E. Coates, P. P. Goodney, and D. P. Croitoru, "Epidural analgesia versus intravenous patient-controlled analgesia following minimally invasive pectus excavatum repair: a systematic review and meta-analysis," *Journal of Pediatric Surgery*, vol. 49, no. 5, pp. 798–806, 2014.

[3] D. Stocki, I. Matot, S. Einav, S. Eventov-Friedman, Y. Ginosar, and C. F. Weiniger, "A randomized controlled trial of the efficacy and respiratory effects of patient-controlled intravenous remifentanil analgesia and patient-controlled epidural analgesia in laboring women," *Anesthesia & Analgesia*, vol. 118, no. 3, pp. 589–597, 2014.

[4] M. P. Bonnet, A. Mignon, J. X. Mazoit, Y. Ozier, and E. Marret, "Analgesic efficacy and adverse effects of epidural morphine compared to parenteral opioids after elective caesarean section: a systematic review," *European Journal of Pain*, vol. 14, no. 9, pp. 894e1–894e9, 2010.

[5] C. M. Bernards, D. D. Shen, E. S. Sterling et al., "Epidural, cerebrospinal fluid, and plasma pharmacokinetics of epidural opioids (part 1)," *Anesthesiology*, vol. 99, no. 2, pp. 455–465, 2003.

[6] W. G. Brose, D. L. Tanelian, J. B. Brodsky, J. B. D. Mark, and M. J. Cousins, "CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration," *Pain*, vol. 45, no. 1, pp. 11–15, 1991.

[7] L. Felden, C. Walter, S. Harder et al., "Comparative clinical effects of hydromorphone and morphine: a meta-analysis," *British Journal of Anaesthesia*, vol. 107, no. 3, pp. 319–328, 2011.

[8] P. Gulur, K. Koury, P. Arnstein et al., "Morphine versus hydromorphone: does choice of opioid influence outcomes?" *Pain Research and Treatment*, vol. 2015, Article ID 482081, 6 pages, 2015.

[9] M. F. Mulroy, "Epidural hydromorphone," *Regional Anesthesia and Pain Medicine*, vol. 35, no. 4, pp. 333–334, 2010.

[10] H. P. Sviggum, K. W. Arendt, A. K. Jacob et al., "Intrathecal hydromorphone and morphine for postcesarean delivery analgesia," *Anesthesia & Analgesia*, vol. 123, no. 3, pp. 690–697, 2016.

[11] N. C. Beatty, K. W. Arendt, A. D. Niesen, E. D. Wittwer, and A. K. Jacob, "Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine," *Journal of Clinical Anesthesia*, vol. 25, no. 5, pp. 379–383, 2013.

[12] M. Gehling and M. Tryba, "Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis," *Anaesthesia*, vol. 64, no. 6, pp. 643–651, 2009.

[13] Z.-M. Xing, Z.-Q. Zhang, W.-S. Zhang, and Y.-F. Liu, "Effects of analgesia methods on serum IL-6 and IL-10 levels after cesarean delivery," *Genetics and Molecular Research*, vol. 14, no. 2, pp. 4778–4783, 2015.

[14] H. Al-Kazwini, I. Sandven, V. Dahl, and L. A. Rosseland, "Prolonging the duration of single-shot intrathecal labour analgesia with morphine: a systematic review," *Scandinavian Journal of Pain*, vol. 13, no. 1, pp. 36–42, 2016.

[15] B. Marroquin, C. Feng, A. Balofsky et al., "Neuraxial opioids for post-caesarean delivery analgesia: can hydromorphone replace morphine? A retrospective study," *International Journal of Obstetric Anesthesia*, vol. 30, pp. 16–22, 2017.

[16] D. H. Chestnut, W. W. Choi, and T. J. Isbell, "Epidural hydromorphone for postcesarean analgesia," *Obstetrics & Gynecology*, vol. 68, no. 1, pp. 65–69, 1986.

[17] S. I. Singh, S. Rehou, K. L. Marmai, and P. M. Jones, "The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia," *Anesthesia & Analgesia*, vol. 117, no. 3, pp. 677–685, 2013.

[18] D. J. Wescules and K. T. Bain, "A systematic review of opioid conversion ratios used with methadone for the treatment of pain," *Pain Medicine*, vol. 9, no. 5, pp. 595–612, 2008.

[19] Y.-S. Lee, Y.-C. Park, J.-H. Kim et al., "Intrathecal hydromorphone added to hyperbaric bupivacaine for postoperative pain relief after knee arthroscopic surgery," *European Journal of Anaesthesiology*, vol. 29, no. 1, pp. 17–21, 2012.

[20] M. S. Shulman, G. Wakerlin, L. Yamaguchi, and J. B. Brodsky, "Experience with epidural hydromorphone for post-thoracotomy pain relief," *Anesthesia & Analgesia*, vol. 66, no. 12, pp. 1331–1333, 1987.

[21] C. M. Palmer, W. M. Nogami, G. Van Maren, and D. M. Alves, "Postcesarean epidural morphine: a dose-response study," *Anesthesia & Analgesia*, vol. 90, no. 4, pp. 887–891, 2000.

[22] H. J. Wüst and P. R. Bromage, "Delayed respiratory arrest after epidural hydromorphone," *Anaesthesia*, vol. 42, no. 4, pp. 404–406, 1987.